|Mr. John Peter McLaughlin||CEO & Director||N/A||N/A||1952|
|Mr. Dominique P. Monnet||Pres||N/A||N/A||1961|
|Mr. Peter S. Garcia||VP & CFO||N/A||N/A||1962|
|Mr. Christopher L. Stone||VP, Gen. Counsel & Sec.||N/A||N/A||1964|
|Mr. Nathan Kryszak||Deputy Gen. Counsel & Assistant Sec.||N/A||N/A||N/A|
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
PDL BioPharma, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 4; Compensation: 2.